中国循证医学杂志

中国循证医学杂志

2017 年 KDIGO 关于慢性肾脏病-矿物质和骨异常(CKD-MBD)临床实践指南的解读

查看全文

关键词: 慢性肾脏病-矿物质和骨异常; 临床实践指南; 指南解读

Key words: Chronic kidney disease-mineral and bone disorder (CKD-MBD); Clinical practice guideline; Guideline interpretation

引用本文: 周莉, 付平. 2017 年 KDIGO 关于慢性肾脏病-矿物质和骨异常(CKD-MBD)临床实践指南的解读. 中国循证医学杂志, 2017, 17(8): 869-875. doi: 10.7507/1672-2531.201708015 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Kidney disease: improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int, 2009, 76 (Suppl 113): S1-S130.
2. Kidney disease: improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017, 7: 1-59
3. EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med, 2012, 367(26): 2482-2494.
4. Block GA, Kilpatrick RD, Lowe KA, et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol, 2013, 8(12): 2132-2140.
5. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant, 2011, 26(6): 1948-1955.
6. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int, 2012, 81(11): 1116-1122.
7. St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol, 2009, 4(2): 354-360.
8. Ok E, Asci G, Bayraktaroglu S, et al. Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis. J Am Soc Nephrol, 2016, 27(8): 2475-2486.
9. Spasovski G, Gelev S, Masin-Spasovska J, et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone, 2007, 41(4): 698-703.
10. Denburg MR, Tsampalieros AK, de Boer IH, et al. Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease. J Clin Endocrinol Metab, 2013, 98(5): 1930-1938.
11. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int, 2013, 83(5): 959-966.
12. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol, 2012, 23(8): 1407-1415.
13. Di Iorio B, Bellasi A, Russo D, et al. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol, 2012, 7(3): 487-493.
14. Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis, 2013, 62(4): 771-778.
15. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet, 2013, 382(9900): 1268-1277.
16. Karavetian M, de Vries N, Elzein H, et al. Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients, Lebanon. Patient Educ Couns, 2015, 98(9): 1116-1122.
17. Lou LM, Caverni A, Gimeno JA, et al. Dietary intervention focused on phosphate intake in hemodialysis patients with hyperphosphoremia. Clin Nephrol, 2012, 77(6): 476-483.
18. Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol, 2009, 4(8): 1370-1373.
19. Oksa A, Spustová V, Krivosíková Z, et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res, 2008, 31(5): 322-329.
20. Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol, 2013, 24(5): 842-852.
21. Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD-the OPERA trial. J Am Soc Nephrol, 2014, 25(1): 175-186.
22. Li XH, Feng L, Yang ZH, et al. The effect of active vitamin d on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis. Nephrology (Carlton), 2015, 20(10): 706-714.
23. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA, 2012, 307(7): 674-684.
24. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant, 2011, 26(4): 1327-1339.
25. Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet hcl therapy to lower cardiovascular events (EVOLVE) trial. Circulation, 2015, 132(1): 27-39.
26. Sprague SM, Wetmore JB, Gurevich K, et al. Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol, 2015, 10(6): 1021-1030.
27. Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int, 2015, 87(4): 846-856.
28. Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study. Nephrol Dial Transplant, 2012, 27(1): 345-351.
29. Naylor KL, Garg AX, Zou G, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol, 2015, 10(4): 646-653.
30. West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res, 2015, 30(5): 913-919.
31. Yenchek RH, Ix JH, Shlipak MG, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol, 2012, 7(7): 1130-1136.
32. Haghverdi F, Mortaji S, Soltani P, et al. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran J Kidney Dis, 2014, 8(6): 461-466.
33. Smerud KT, Dolgos S, Olsen IC, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am J Transplant, 2012, 12(12): 3316-3325.
34. Sanchez-Escuredo A, Fuster D, Rubello D, et al. Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nucl Med Commun, 2015, 36(8): 815-818.
35. Torregrosa JV, Fuster D, Gentil MA, et al. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation, 2010, 89(12): 1476-1481.
36. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res, 2011, 26(8): 1829-1835.
37. 鲁瑶, 孙小亮, 张凌, 等. 甲状旁腺全切除治疗继发性甲状旁腺功能亢进. 中日友好医院学报, 2017, 2(31): 79-81.